International Aids Vaccine Initiative is a international development organization based in New York, NY that was founded in 1996. As of 2019 they had $77 million in revenue and $83 million in assets.
International Aids Vaccine Initiative (iavi) is a global Initiative dedicated to ensure the development of safe, effective, accessible, preventive hiv vaccines for use throughout the world. A global Initiative for safe, effective, accessible, preventi...
Previous legal names or variations of their name include: Aids Vaccine Initiative International.
Research and development: through scientific and clinical research in africa, india, europe, and the u.s., iavi develops vaccines and antibodies in and for the developing world and seeks to accelerate their introduction in low-income countries. Iavi advances scientific discovery and development by fostering unique collaborations among academia, industry, local communities, governments, and funders to explore new and better ways to address public health threats that disproportionately affect people living in poverty. Vaccine and antibody candidates are put through a rigorous process of clinical evaluation among key populations to establish their safety and efficacy, an effort that enables iavi to strengthen the healthcare infrastructure and scientific capacity of countries where our clinical partners operate. To date, iavi and its partners have advanced more than 30 hiv Vaccine candidates into early stage clinical trials. This includes the first hiv Vaccine trials in sub-saharan countries, where the hiv burden is greatest. Iavi has ...
Vaccine advocacy, public affairs, and policy: iavi works with policy makers, advocates, and representatives of the communities where disease burden is greatest to support scientific research and development for accessible biomedical preventives and treatments.
Contract manufacturing-related activities: iavi supports external researchers by providing technical and scientific expertise to accelerate the development of their own products.
| Fiscal year ending | Date received by IRS | Form | PDF link |
|---|---|---|---|
| 2018-12 | Oct 12, 2019 | 990 | View PDF |
| 2017-12 | Oct 16, 2018 | 990 | View PDF |
| 2016-12 | Oct 23, 2017 | 990 | View PDF |
| 2015-12 | Nov 2, 2016 | 990 | View PDF |
| 2014-12 | Jul 27, 2015 | 990 | View PDF |
| ...and five more Form 990 PDFs | |||
| Field | 2018 |
|---|---|
| Total grants, contributions, etc. | $75,524,844 |
| Program services | $396,577 |
| Investment income and dividends | $921,661 |
| Tax-exempt bond proceeds | $0 |
| Royalty revenue | $0 |
| Net rental income | $0 |
| Net gain from sale of non-inventory assets | $0 |
| Net income from fundraising events | $0 |
| Net income from gaming activities | $0 |
| Net income from sales of inventory | $0 |
| Miscellaneous revenues | $349,691 |
| Total revenues | $77,192,773 |
| Vendor | Services | Amount paid | Date |
|---|---|---|---|
| Blackbaud | CRM software; Fundraising software | 2019-12-04 | |
| ██████ █████████ ███ ████████ | Audit accounting; Tax accounting | 2019-09-16 | |
| ██████ █████ | Legal Services | $188,537 | 2018-12-01 |
| █████ ███████████ | Clinical Research Studies | $765,799 | 2018-12-01 |
| ██████████ █████████ ███ ███ | Regulatory Consultant | $330,878 | 2018-12-01 |
| ██████ █ ███████ | Video Ethnography | $512,748 | 2018-12-01 |
| ███ ██████████ ████████ ███ | Temp Services | $505,954 | 2018-12-01 |
| █████ | Insurance | 2018-06-30 | |
| ...and 13 more vendors | |||
| Name | Title | Compensation | Most recent data |
|---|---|---|---|
| Ana Cespedes Montoya | Chief Operating Officer | $113,846 | Dec. 31, 2018 |
| Louis D Schwartz | Chief Financial Officer | $324,722 | Sept. 16, 2019 |
| ███████ ██████ | Executive Director , Chief Medical Officer / Chief Medical Officer and Executive Director , Medical Affairs | $299,146 | Dec. 31, 2018 |
| ███████ ███████ | H.R , Asst Secretary / Vice President , Human Resources | $244,969 | Dec. 31, 2018 |
| █████ █████ | Vice President Research Integration and Innov. / Vice President , Research Integration and Innovation | $319,471 | Dec. 31, 2018 |
| ████████ ████████ | Vice President , Global Affairs | - | Jan. 23, 2018 |
| ████████ █ █████ | Vice President Global All and Product / Vice President , Global Alliances and Product Optimization | $311,679 | Dec. 31, 2018 |
| ██████ ███████ | Vice President Vaccine Development R and D / Vice President for Vaccine Development | $345,158 | Dec. 31, 2018 |
| ████ ███████ | Executive Director for Human Immunology and Principal Investigator of the Iavi Human Immunology Laboratory at Imperial College L | - | Jan. 23, 2018 |
| ██████ ██████ | Secretary , Senior Vice President , General Counsel | $378,295 | Dec. 31, 2018 |
| ...and 12 more key personnel | |||